Digoxin indications and usage: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{XXXXX}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LANOXIN (DIGOXIN) TABLET [COVIS PHARMACEUTICALS, INC.]...")
 
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{XXXXX}}
{{Digoxin}}
{{CMG}}; {{AE}} {{AZ}}
{{CMG}}; {{AE}} {{AZ}}



Revision as of 00:06, 30 January 2014

Digoxin
DIGOXIN injection® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
DIGOXIN tablet® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]


[1]

References

  1. "LANOXIN (DIGOXIN) TABLET [COVIS PHARMACEUTICALS, INC.]".

Adapted from the FDA Package Insert.